Baris Deniz

All-Cause and Incremental Per Patient Per Year Cost Associated with Chronic Hepatitis C Virus and Associated Liver Complications in the United States: A Managed Care Perspective

Carrie McAdam‐Marx, Lisa J. McGarry, Christopher A. Hane et al. · Journal of Managed Care Pharmacy · 2011 · 166 citations · Full text

The Effect of Hepatitis C Treatment Response on Medical Costs: A Longitudinal Analysis in an Integrated Care Setting

M. Michele Manos, Jeanne Darbinian, Jaime Rubin et al. · Journal of Managed Care Pharmacy · 2013 · 50 citations · Full text

The economic burden of advanced liver disease among patients with Hepatitis C Virus: a large state Medicaid perspective

Joseph Menzin, Leigh Ann White, Christine Nichols et al. · BMC Health Services Research · 2012 · 34 citations · Full text

The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada

Wenqing Su, Colin Vicente, Baris Deniz et al. · Journal of Medical Economics · 2016 · 30 citations

Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C

Anita J. Brogan, Sandra E. Talbird, James R. Thompson et al. · PLoS ONE · 2014 · 21 citations · Full text